Inclusion Criteria:

          -  Age ≥ 18

          -  Confirmation of GBM (WHO grade IV).

          -  Maximal debulking surgery and undergo radiotherapy concomitant with Temozolomide
             (45-70Gy)

          -  Stable disease after treatment of radiation with chemotherapy

          -  Life expectancy > 16 weeks.

          -  Performance status of 0-2 (Eastern Cooperative Oncology Group).

          -  First vaccine treatment start date at least 4 weeks out but not more than 8 weeks from
             the last dose of concomitant Temozolomide or radiotherapy.

          -  Must have tumor tissue sufficient sequencing.

          -  Have adequate bone marrow function

          -  Require Dexamethasone ≤ 4mg daily on a stable dose

          -  Acceptable hematologic, hepatic, and renal function and these tests must be performed
             within 14 days prior to study

          -  The participant must be deemed competent to give informed consent.

          -  The participant must agree to use two effective forms of contraception beginning at
             least four (4) weeks prior to study entry.

        Exclusion Criteria:

          -  Progression of disease at time of screening.

          -  Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other
             implanted electronic devices in the brain, or documented clinically significant
             arrhythmias.

          -  Infra-tentorial tumor or multifocal disease.

          -  History of hypersensitivity reaction to Temozolomide.

          -  Receiving any other investigational agents.

          -  Prior history of unrelated neoplastic disease, and having received systemic therapy
             for the secondary malignancy within the twelve (12) month period preceding the
             screening evaluation.

          -  (HIV/AIDS), Chronic hepatitis B or hepatitis C.

          -  History of, or is reasonably suspected to meet criteria for the diagnosis of a known
             congenital or acquired disorder causing systemic immunosuppression.

          -  History of, or is reasonably suspected to meet criteria for the diagnosis of a
             systemic auto-immune/inflammatory disease or other autoimmune disorder with the
             exception of: Vitiligo

          -  Positive pregnancy test [45 CFR 46.203(b)].